SCHEMBL577323

SCHEMBL577323

COC(=O)C(C)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 6/20 1.00
PTGS2 P35354 6/20 1.00
MAPT P10636 5/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
ALDH1A1 P00352 3/20 0.71
LMNA P02545 3/20 0.71
CXCR1 P25024 2/20 0.71
CXCR2 P25025 2/20 0.71
CYP3A4 P08684 2/20 0.71
RECQL P46063 1/20 0.71
KDM4E B2RXH2 1/20 0.71
HPGD P15428 1/20 0.71
MAPK1 P28482 1/20 0.71
PMP22 Q01453 1/20 0.71
SLC22A6 Q4U2R8 1/20 0.71
HSD17B10 Q99714 1/20 0.71
CXCL8 P10145 1/20 0.71
THPO P40225 1/20 0.71
HIF1A Q16665 1/20 0.71
HTT P42858 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9086931 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL8754918 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL12935378 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL10420237 0.90 PTGS1 (0.81) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL6430962 0.89 PTGS2 (0.80) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL11444866 0.88 PTGS1 (0.79) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL20079537 0.88 PTGS2 (0.78) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL31455828 0.87 PTGS1 (0.77) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL7484343 0.87 PTGS1 (0.76) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL4733889 0.86 PTGS2 (0.76) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5322791-A Enantiospecific hydrolysis WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1994-06-21 US claimed
EP-0227078-A1 Process for preparing (S)-alpha-methylarylacetic acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1987-07-01 EP claimed
US-20250241922-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) 2025-07-31 US disclosed
US-20250241921-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) 2025-07-31 US disclosed
US-12290519-B2 Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2025-05-06 US disclosed
US-20240197741-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) 2024-06-20 US disclosed
EP-4357346-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF Coval Biopharma (Shanghai) Co., Ltd. (CN) 2024-04-24 EP disclosed
WO-2023001045-A9 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-10-26 WO disclosed
WO-2023010200-A1 THERAPEUTIC COORDINATION POLYMERS CONTAINING PHARMACEUTICALS FOR DRUG RELEASE APPLICATIONS UNIVERSITY OF WINDSOR (CA) 2023-02-09 WO disclosed
WO-2023001045-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-01-26 WO disclosed
EP-3082762-B1 LONG-ACTING KETOPROFEN COMPOSITIONS ZOETIS SERVICES LLC (US) 2021-11-17 EP disclosed
EP-0422235-A1 PRODUCTION OF alpha-(3-BENZOYLPHENYL)PROPIONIC ACID DERIVATIVE NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1991-04-17 EP disclosed
EP-0227078-A1 Process for preparing (S)-alpha-methylarylacetic acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1987-07-01 EP disclosed
US-4308208-A α-Methylthio-α-(p-phthalimidophenyl)-propionic acid SAGAMI CHEMICAL RESEARCH CENTER (JP) 1981-12-29 US disclosed
US-4278802-A METHYLTHIO-/P-/2-THIENYLCARBONYL/PHENYL/PROPIONIC ACID OR ESTER, PHARMACEUTICAL INTERMEDIATES SAGAMI CHEMICAL RESEARCH CENTER (JP) 1981-07-14 US disclosed
US-4242519-A DRUG INTERMEDIATES SAGAMI CHEMICAL RESEARCH CENTER (JP) 1980-12-30 US disclosed
US-4237298-A Aromatic acetic acid derivatives having sulfur atom at alpha-position and process for their preparation SAGAMI CHEMICAL RESEARCH CENTER (JP) 1980-12-02 US disclosed
US-4144248-A Aromatic acetic acid derivatives having sulfur atom at alpha-position and process for their preparation SAGAMI CHEMICAL RESEARCH CENTER (JP) 1979-03-13 US disclosed
US-3995056-A Butyric acid derivatives for treating pain and inflammation ROUSSEL-UCLAF (FR) 1976-11-30 US disclosed
US-3931302-A ANTIINFLAMMATORY, ANALGESIC ROUSSEL-UCLAF (FR) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241921-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF JAK1, TNF, CYP4A11 PTGS1 16/4885PTGS2 37/4885MAPT 4357/4885
US-12290519-B2 Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof JAK1, TNF, CYP4A11 PTGS1 16/4885PTGS2 37/4885MAPT 4357/4885
US-20250241922-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF JAK1, TNF, CYP4A11 PTGS1 16/4885PTGS2 37/4885MAPT 4357/4885
US-20240197741-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF TNF, CYP4A11, JAK1 PTGS1 16/4885PTGS2 36/4885MAPT 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.